{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AS03", "query": { "intervention": "AS03" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 31, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AS03&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T03:17:14.614Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04762680", "title": "Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3159, "start_date": "2021-02-24", "completion_date": "2023-06-29", "has_results": true, "last_update_posted_date": "2025-09-18", "last_synced_at": "2026-09-02T03:17:14.614Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04762680" }, { "nct_id": "NCT03318315", "title": "Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Avian Influenza", "Influenza", "Influenza Immunisation" ], "interventions": [ { "name": "AS03", "type": "DRUG" }, { "name": "Inactivated influenza H7N9 vaccine", "type": "BIOLOGICAL" }, { "name": "Influenza Virus Quadrivalent Inactivated Vaccine", "type": "BIOLOGICAL" }, { "name": "Phosphate Buffered Saline (PBS) diluent", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "19 Years to 64 Years" }, "enrollment_count": 149, "start_date": "2018-02-20", "completion_date": "2019-07-25", "has_results": true, "last_update_posted_date": "2020-08-06", "last_synced_at": "2026-09-02T03:17:14.614Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03318315" }, { "nct_id": "NCT03014310", "title": "H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Avian Influenza" ], "interventions": [ { "name": "AS03", "type": "DRUG" }, { "name": "MF59", "type": "DRUG" }, { "name": "Monovalent Influenza A/H5N8 vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "19 Years to 64 Years" }, "enrollment_count": 388, "start_date": "2017-01-09", "completion_date": "2018-12-19", "has_results": false, "last_update_posted_date": "2024-09-23", "last_synced_at": "2026-09-02T03:17:14.614Z", "location_count": 7, "location_summary": "Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03014310" }, { "nct_id": "NCT01573312", "title": "H5N1 Vaccination With and Without AS03: Systems Biology Analysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "ASO3 Adjuvant", "type": "DRUG" }, { "name": "Influenza A/H5N1 Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 20, "start_date": "2012-05-24", "completion_date": "2014-01-02", "has_results": false, "last_update_posted_date": "2019-10-21", "last_synced_at": "2026-09-02T03:17:14.614Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01573312" }, { "nct_id": "NCT03589807", "title": "2013/2017 H7N9 Prime-Boost Interval", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Avian Influenza", "Influenza Immunisation" ], "interventions": [ { "name": "A/H7N9", "type": "BIOLOGICAL" }, { "name": "AS03", "type": "DRUG" }, { "name": "Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013", "type": "BIOLOGICAL" }, { "name": "Phosphate Buffered Saline (PBS) diluent", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "19 Years to 50 Years" }, "enrollment_count": 180, "start_date": "2018-08-21", "completion_date": "2020-06-14", "has_results": true, "last_update_posted_date": "2021-08-02", "last_synced_at": "2026-09-02T03:17:14.614Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Decatur, Georgia • Iowa City, Iowa + 3 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03589807" }, { "nct_id": "NCT03300050", "title": "Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza", "Vaccine" ], "interventions": [ { "name": "cH8/1N1 LAIV", "type": "BIOLOGICAL" }, { "name": "AS03-adjuvanted cH5/1N1 IIV", "type": "BIOLOGICAL" }, { "name": "cH5/1N1 IIV", "type": "BIOLOGICAL" }, { "name": "AS03-adjuvanted cH8/1N1 IIV", "type": "BIOLOGICAL" }, { "name": "Normal saline", "type": "BIOLOGICAL" }, { "name": "Phosphate buffered saline (PBS)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "PATH", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 65, "start_date": "2017-10-10", "completion_date": "2019-08-09", "has_results": true, "last_update_posted_date": "2021-02-21", "last_synced_at": "2026-09-02T03:17:14.614Z", "location_count": 2, "location_summary": "Durham, North Carolina • Cincinnati, Ohio", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03300050" }, { "nct_id": "NCT01910519", "title": "Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza A Virus, H5N1 Subtype" ], "interventions": [ { "name": "H5N1 vaccine plus AS03 adjuvant", "type": "BIOLOGICAL" }, { "name": "H5N1 vaccine without adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "21 Years to 45 Years" }, "enrollment_count": 50, "start_date": "2013-07", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2019-02-12", "last_synced_at": "2026-09-02T03:17:14.614Z", "location_count": 1, "location_summary": "Decatur, Georgia", "locations": [ { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01910519" }, { "nct_id": "NCT01934127", "title": "Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Investigational H7N1 vaccine GSK2789869A", "type": "BIOLOGICAL" }, { "name": "Investigational H7N1 vaccine GSK2789868A", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "21 Years to 64 Years" }, "enrollment_count": 427, "start_date": "2013-08-26", "completion_date": "2014-10-20", "has_results": false, "last_update_posted_date": "2017-05-08", "last_synced_at": "2026-09-02T03:17:14.614Z", "location_count": 6, "location_summary": "Miami, Florida • Stockbridge, Georgia • Las Vegas, Nevada + 3 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Stockbridge", "state": "Georgia" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Rochester", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01934127" }, { "nct_id": "NCT00963157", "title": "Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "AS03", "type": "DRUG" }, { "name": "Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 789, "start_date": "2009-09", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2014-12-24", "last_synced_at": "2026-09-02T03:17:14.614Z", "location_count": 7, "location_summary": "Stanford, California • Decatur, Georgia • Iowa City, Iowa + 3 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00963157" }, { "nct_id": "NCT05518487", "title": "COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19", "Kidney Transplant" ], "interventions": [ { "name": "Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2023-02-20", "completion_date": "2024-11-06", "has_results": true, "last_update_posted_date": "2025-06-25", "last_synced_at": "2026-09-02T03:17:14.614Z", "location_count": 6, "location_summary": "San Diego, California • San Francisco, California • Atlanta, Georgia + 3 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05518487" } ] }